• 1
    DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992; 10: 635643.
  • 2
    Herrlinger U, Brugger W, Bamberg M, et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology. 2000; 54: 17071708.
  • 3
    Ciordia R, Hochberg FH, Batchelor TT. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 165a.
  • 4
    McLaughlin P, Velasquez WS, Redman JR, et al. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst. 1988; 80: 14081412.
  • 5
    Coiffer B, LePage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 246: 235242.
  • 6
    Lachance DH, Brizel DM, Gockerman JP, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology. 1994; 44: 17211727.
  • 7
    Raizer JJ, DeAngelis LM, Zelenetz AE, et al. Activity of rituximab in primary central nervous system lymphoma (PCNSL) [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 166a.
  • 8
    Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003; 101: 466468.
  • 9
    Marzolini C, Decosterd LA, Shen F, et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol. 1998; 42: 433440.
  • 10
    Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002; 29: 29.
  • 11
    Stewart PA. Endothelial vesicles in the blood-brain barrier: are they related to permeability? Cell Mol Neurobiol. 2000; 20: 149163.
  • 12
    Reni M, Ferreri AJ, Landoni C, et al. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst. 2000; 92: 575576.
  • 13
    Lerro KA, Lacy J. Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol. 2002; 59: 165168.
  • 14
    Herrlinger U, Küker W, Platten M, et al. First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology. 2002; 58: 15731574.
  • 15
    Angelov L, Vogelbaum MA, Barnett GH, et al. Primary central nervous system lymphoma: response to temozolomide therapy [abstract]. Neuro-oncol. 2003; 5: 347.
  • 16
    Quinn J, Reardon D, Rich J, et al. Phase II treatment of adults with newly diagnosed, progressive, or recurrent primary central nervous system lymphoma with Temodar [abstract]. Neuro-oncol. 2003; 5: 354.
  • 17
    Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001; 7: 709723.
  • 18
    Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001; 61: 51375144.
  • 19
    Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994; 84: 24572466.
  • 20
    Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000; 18: 31353143.
  • 21
    Lopez A, Palacios C, Perez-Manga G, et al. Final results of a Phase II study to evaluate the efficacy and safety of treatment and retreatment with rituximab in relapsed follicular or low-grade NHL [abstract]. Blood. 2001; 98: 604a.
  • 22
    Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003; 21: 17461751.